Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04155047 · ClinicalTrials.gov registry record · Phase 4
A Clinical Study to Investigate if a Single Dose of an Approved Drug Product (Glycopyrrolate Inhalation Solution) Reduces Trapped Air in the Lungs of Participants With Chronic Obstructive Pulmonary Disease.
A Phase 4 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by Sunovion Respiratory Development.
- Completed
- Registry status
- Phase 4
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT04155047 is a Phase 4 study of Chronic Obstructive Pulmonary Disease (COPD) that has completed, run by Sunovion Respiratory Development. The registered enrollment target is 44 participants, below the 650-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04155047, a Phase 4 study of Chronic Obstructive Pulmonary Disease (COPD), has completed, sponsored by Sunovion Respiratory Development.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
A clinical study to investigate if a single dose of an approved drug product (glycopyrrolate Inhalation Solution) reduces trapped air in the lungs of participants with chronic obstructive pulmonary disease. This study is accepting male and female participants over the age of 40. The study will be conducted at one site located in the United States.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Glyocopyrrolate Inhalation Solution administered by Magnair
- DRUG Placebo administered by Magnair
Study Locations (1)
Missouri
- Midwest Chest Consultants - Saint Charles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2019-11-07 |
| Est. Completion | 2020-03-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04155047
The ClinicalTrials.gov registry entry for NCT04155047 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 650-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (93% lower). The listed sponsor is Sunovion Respiratory Development, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease (COPD) appearing as the primary indexed condition, and to 2 interventions - of which Glyocopyrrolate Inhalation Solution administered by Magnair is the first listed.
NCT04155047 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT04155047 about?
NCT04155047 is a clinical study titled "A Clinical Study to Investigate if a Single Dose of an Approved Drug Product (Glycopyrrolate Inhalation Solution) Reduces Trapped Air in the Lungs of Participants With Chronic Obstructive Pulmonary Disease.". A clinical study to investigate if a single dose of an approved drug product (glycopyrrolate Inhalation Solution) reduces trapped air in the lungs of participants with chronic obstructive pulmonary disease. This study is accepting male and female participants over the age of 40. The study will be co...
What is the current status of trial NCT04155047?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 44 participants. The study started on 2019-11-07. Estimated completion is 2020-03-31.
What conditions does trial NCT04155047 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease (COPD).
What interventions are being tested in trial NCT04155047?
The interventions under investigation include: Glyocopyrrolate Inhalation Solution administered by Magnair (COMBINATION_PRODUCT), Placebo administered by Magnair (DRUG).
Who is sponsoring clinical trial NCT04155047?
This trial is sponsored by Sunovion Respiratory Development, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04155047 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease (COPD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adherence Study in COPD Patients
COMPLETED · Phase 4
-
Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
RECRUITING
-
Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
RECRUITING · Phase 2
-
Multi-Center Clean Air Randomized Controlled Trial in COPD
RECRUITING · Phase 3
-
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.